2.93
-0.18(-5.79%)
Currency In USD
| Previous Close | NaN |
| Open | NaN |
| Day High | NaN |
| Day Low | NaN |
| 52-Week High | NaN |
| 52-Week Low | NaN |
| Volume | NaN |
| Average Volume | NaN |
| Market Cap | NaN |
| PE | NaN |
| EPS | NaN |
| Moving Average 50 Days | NaN |
| Moving Average 200 Days | NaN |
| Change | NaN |
If you invested $1000 in Jasper Therapeutics, Inc. (JSPR) since IPO date, it would be worth $29.84 as of August 18, 2025 at a share price of $2.93. Whereas If you bought $1000 worth of Jasper Therapeutics, Inc. (JSPR) shares 3 years ago, it would be worth $136.28 as of August 18, 2025 at a share price of $2.93.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Data not available
Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway
GlobeNewswire Inc.
Jul 09, 2025 12:00 PM GMT
Reducing workforce by approximately 50% to focus on Chronic Urticaria programs and extend cash runway Dr. Edwin Tucker departing as Chief Medical Officer; Dr. Daniel Adelman to serve as Acting Chief Medical Officer REDWOOD CITY, Calif., July 09, 202
Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria
GlobeNewswire Inc.
Jul 07, 2025 11:30 AM GMT
8 of 9 participants (89%) treated in the 240mg and 360mg single dose cohorts achieved a complete response 8 of 11 participants (73%) enrolled in the 180mg Q8W open label extension study achieved a complete response at 12 weeks Results from the 240m
Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
GlobeNewswire Inc.
Jun 14, 2025 2:00 PM GMT
11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in the 180mg cohort achieved a clinical response Tryptase levels below the lower limit of quantification observed in 10 of 12 participa